Clopidogrel
- TRADE NAME: Plavix (Bristol-Myers Squibb, Sanofi-Aventis)
- INDICATIONS: Acute coronary syndrome, recent myocardial infarction, recent stroke, or established peripheral arterial disease
- CLASS: Antiplatelet, Antiplatelet; thienopyridine
- HALF-LIFE: 6 hours
Amiodarone, Anisindione, Anticoagulants, Atorvastatin, Calcium channel blockers, Cangrelor, Carbamazepine, Chloramphenicol, Cimetidine, Ciprofloxacin, Collagenase, Dabigatran, Dasatinib, Delavirdine, Dexlansoprazole, Diclofenac, Dicumarol, Dipyridamole, Drotrecogin Alfa, Efavirenz, Enoxaparin, Erythromycin, Esomeprazole, Etravirine, Fluconazole, Fluoxetine, Fluvoxamine, Fondaparinux, Glucosamine, Herbals with anticoagulant properties, Ibritumomab, Iloprost, Inotersen, Itraconazole, Ketoconazole, Lansoprazole, Lepirudin, Macrolide antibiotics, Meloxicam, Miconazole, Moclobemide, NSAIDs, Omega-3 Fatty Acids, Omeprazole, Oxcarbazepine, Pantoprazole, Pentosan, Pentoxifylline, Polysulfate sodium, Prasugrel, Rabeprazole, Rifapentine, Rivaroxaban, Salicylates, Simvastatin, Telithromycin, Thrombolytic agents, Tinzaparin, Tositumomab & Iodine131, Voriconazole, Warfarin
PREGNANCY CATEGORY: B
Contra-indicated in patients with active pathological bleeding.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of clopidogrel in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/03/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
